通过改变EAE多发性硬化症小鼠模型中的胆固醇代谢,analgecine的神经保护作用
Cuicui Yang1, Xinhai Jiang2, Zizhao Cheng3
1Department of Clinical Trial Center, Beijing Tiantan Hospital, Capital Medical University, Beijing 100070, China.
Journal of neuroimmunology
|August 3, 2025
概括
抗痛药 (AGC) 可以通过改善胆固醇平衡和减少神经损伤来治疗多发性硬化症 (MS). 这项研究表明,AGC在MS小鼠模型中减轻了脱髓化和神经元损失,提供了潜在的新疗法.
科学领域:
- 神经科学是一个神经科学.
- 免疫学 免疫学 免疫学
- 生物化学 生物化学
背景情况:
- 多发性硬化症 (MS) 是一种慢性自身免疫神经疾病,导致脱髓化和有限的治疗选择.
- 胆固醇稳态干预正在MS患者的复髓化方面进行探索.
- 的皮肤提取物analgecine (AGC) 已证明具有神经保护作用.
研究的目的:
- 在多发性硬化症 (MS) 的小鼠模型中研究Analgecine (AGC) 对胆固醇平衡的作用和机制.
- 通过检查其对神经系统缺陷,脱髓化和神经元损失的影响,评估AGC对MS的潜在治疗益处.
主要方法:
- 利用一种实验性自身免疫性脑膜炎 (EAE) 鼠标模型来模拟MS.
- 评估神经缺陷得分和体重变化.
- 通过组织学检查,通过组织学检查分析了脊髓和体的脱髓化.
- 在海马和皮质区域评估了神经元完整性.
- 采用蛋白质组分析来确定分子机制,重点关注胆固醇代谢和DHCR24基因表达.
- 研究了AGC对微质中的胆固醇聚合的影响,无论是体外还是体内.
主要成果:
- 在EAE小鼠中,AGC治疗显著降低了神经缺陷得分,并改善了体重.
- 在脊髓和体中,AGC减弱的脱化.
- 治疗修改了海马和皮质中的神经元损失.
- 蛋白质组分析表明,AGC调节胆固醇代谢,可能通过DHCR24基因表达.
- AGC有效地缓解了微质中的异常胆固醇聚合.
结论:
- 分析剂 (AGC) 显示出对多发性硬化症 (MS) 的显著治疗潜力.
- 通过减少脱髓化和神经元损失,AGC可以改善多发性硬化症状.
- AGC的治疗效果可能与其调节胆固醇代谢平衡和缓解微质中的胆固醇聚合的能力有关.
更多相关视频
09:38Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
Published on: September 12, 2016
12.4K
04:43Author Spotlight: Insights and Innovations in Gene Expression Manipulation Techniques for Choroid Plexus Research
Published on: June 16, 2023
1.1K
相关概念视频
Indirect-Acting Cholinergic Agonists: Pharmacological Actions
832
Indirect-acting cholinergic agonists, also known as anticholinesterases, exert their pharmacological effects by enhancing cholinergic transmission in various body parts, including the neuromuscular junction, autonomic cholinergic synapses, and the brain.
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
832
Alzheimer's Disease: Treatment
262
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
262
